Aspire Biopharma (NASDAQ: ASBP) adds Series A non-voting convertible preferred

Rhea-AI Filing Summary

Aspire Biopharma Holdings, Inc. amended its charter to designate 25,000 shares of authorized preferred stock as Series A Convertible Non-Voting Preferred Stock. These shares are convertible into common stock at a price equal to 80% of the lowest closing price over the five trading days before conversion, subject to a floor equal to 20% of the Nasdaq “Minimum Price” and other adjustments.

Conversions are limited so that an investor generally cannot own more than 4.99% of outstanding common shares, with the option to increase this cap up to 9.99% on 61 days’ notice, and total issuances from conversion cannot exceed 19.99% of common shares outstanding without required shareholder approval. The Series A ranks senior to common stock on liquidation, has anti-dilution price protection, carries participation rights for up to 30% of certain future financings for six months, receives dividends on an as-converted basis when common stock receives non-stock dividends, and has no regular voting rights beyond those required by law or the charter.

Insights

Equity capital markets analyst

Aspire adds anti-dilutive, non-voting preferred with capped common-stock conversion.

Aspire Biopharma has created 25,000 shares of Series A Convertible Preferred that sit senior to common stock in liquidation and convert into common at a discount formula: 80% of the lowest closing price over five prior trading days, subject to a Nasdaq-linked floor.

The structure includes strong price-protection features. If new, non-exempt securities are issued below the then-current conversion price, the conversion price resets to the lower level, but not below the stated floor. This can meaningfully increase the number of common shares issuable upon conversion over time.

Conversion is constrained by ownership limits. Individual holders are generally capped at 4.99% beneficial ownership, adjustable up to 9.99% after 61 days’ notice, and total issuances from conversions cannot exceed 19.99% of common shares without shareholder approval under Nasdaq rules. The preferred is non-voting, but holders receive as-converted dividends and can participate in up to 30% of qualifying financings for six months after issuance.

false --12-31 0001847345 0001847345 2026-02-02 2026-02-02 0001847345 ASBP:CommonStockParValue0.0001PerShareMember 2026-02-02 2026-02-02 0001847345 ASBP:WarrantsEachExercisableForOneShareOfCommonStockMember 2026-02-02 2026-02-02 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 2, 2026

Aspire Biopharma Holdings, Inc.

(Exact Name of Registrant as Specified in Its Charter)

Delaware		001-41293		33-3467744
(State or other jurisdiction of incorporation)		(Commission File No.)		(I.R.S. Employer Identification No.)

23150 Fashion Drive, Suite 232

Estero, Florida 33928

(Address of Principal Executive Offices)

(415) 592-7399

(Registrant’s Telephone Number)

194 Candelaro Drive, #233

Humacao, PR 00791

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, par value $0.0001 per share		ASBP		The Nasdaq Stock Market LLC
Warrants, each exercisable for one share of common stock		ASBPW		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.03 Amendments to Articles of Incorporation or Bylaws.

Series A Preferred Stock

The information contained above in Item 1.01 is hereby incorporated by reference into this Item 5.03.

Pursuant to the terms of the Securities Purchase Agreement, on February 2, 2026, the Company filed the Certificate of Designation with the Delaware Secretary of State designating, 25,000 shares of its authorized and unissued preferred stock as Series A Convertible Preferred Stock. The Certificate of Designation sets forth the rights, preferences and limitations of the shares of Preferred Stock. Terms not otherwise defined in this item shall have the meanings given in the Certificate of Designation.

The following is a summary of the terms of the Preferred Stock:

Conversion. Pursuant to the Certificate of Designation, which is filed as Exhibit 3.1 to this Current Report on Form 8-K (the “Certificate of Designation”), each share of Preferred Stock, subject to the Stockholder Approval (as defined in the Certificate of Designation), is convertible at the option of the holder into shares of Common Stock at a conversion price equal to 80% of the lowest closing price of our Common Stock as of the closing of the Principal Market (as such term is defined in the Certificate of Designation) for each of the five (5) Trading Days (as such term is defined in the Certificate of Designation) immediately prior to the date of conversion, or other date of determination (but in no event less than the floor price), subject to certain adjustments as set forth in the Certificate of Designation (the “Conversion Price”). The floor price is equal to 20% of the Minimum Price (as such term is defined by the rules and regulations of the Nasdaq Stock Market LLC, Rule 5635(d)(1)(A)) (or such lower amount as permitted, from time to time, by the Principal Market (the “Floor Price”). The number of shares of Common Stock issuable upon conversion of a share of Preferred Stock shall be determined by dividing (x) the stated value of the Preferred Stock to be converted by (y) the Conversion Price.

The shares of Preferred Stock will be convertible immediately upon issuance, at the option of the holder, at the Conversion Price, subject to a conversion cap that limits the conversion of the Preferred Stock such that an Investor may not beneficially own more than 4.99% (the “Maximum Percentage”) of the shares of Common Stock that would be issued and outstanding following such conversion. An Investor may decrease or increase the Maximum Percentage by written notice to the Company from time to time to any other percentage not in excess of 9.99%, provided that any increase in the Maximum Percentage will not be effective until the sixty-first (61st) day after such notice is delivered to the Company, provided further that a holder shall not convert any Preferred Stock to the extent that, after giving effect to such conversion, the aggregate number of shares of Common Stock issued or issuable upon conversion of the Preferred Stock would exceed 19.99% of the issued and outstanding shares of the Company’s Common Stock unless and until the Company has obtained the shareholder approval required by Nasdaq Listing Rule 5636(d).

Ranking. The Series A shall rank (i) senior to all of the Common Stock; (ii) senior to any class or series of capital stock of the Corporation hereafter created specifically ranking by its terms junior to any Series A (“Junior Securities”); (iii) on parity with any class or series of capital stock of the Corporation created specifically ranking by its terms on parity with the Preferred Stock (“Parity Securities”); and (iv) junior to any class or series of capital stock of the Corporation hereafter created specifically ranking by its terms senior to any Series A (“Senior Securities”), in each case, as to dividends or distributions of assets upon liquidation, dissolution or winding up of the Corporation, whether voluntarily or involuntarily. Subject to any superior liquidation rights of the holders of any Senior Securities of the Corporation and the rights of the Corporation’s existing and future creditors, upon any liquidation, dissolution or winding-up of the Corporation, whether voluntary or involuntary (a “Liquidation”), each Holder shall be entitled to be paid out of the assets of the Corporation legally available for distribution to stockholders, prior and in preference to any distribution of any of the assets or surplus funds of the Corporation to the holders of the Common Stock and Junior Securities and pari passu with any distribution to the holders of Parity Securities, an amount equal to the Stated Value for each share of Series A held by such Holder and an amount equal to any accrued and unpaid dividends thereon, and thereafter the Holders shall be entitled to receive out of the assets, whether capital or surplus, of the Corporation the same amount that a holder of Common Stock would receive if the Seres A were fully converted (disregarding for such purposes any conversion limitations hereunder) to Common Stock which amounts shall be paid pari passu with all holders of Common Stock. The Corporation shall mail written notice of any such Liquidation, not less than sixty (60) days prior to the payment date stated therein, to each Holder.

Price Protection. Except for any Exempt Issuance, in the event the Corporation issues or sells any securities including Options or Convertible Securities (or amends any outstanding securities of the Company), at an effective price of, or with an exercise or conversion price of less than the Conversion Price, then upon such issuance or sale, the Conversion Price shall be reduced to the lesser of (i) the Floor Price; or (ii) the sale price or the exercise or conversion price of the securities issued or sold. In case any shares of Common Stock, Convertible Securities or Options are issued in connection with the issue or sale of other securities of the Company, together comprising one integrated transaction, each share of Common Stock underlying any such Convertible Securities or Options shall be deemed to be one additional share of Common Stock for the purposes of determining the effective price of the non-Exempt Issuance.

Participation Rights. Subject to certain terms and conditions in the Certificate of Designation, until the six (6) month anniversary of the issuance of the Series A to the Holder, upon any Subsequent Financing, the Holders of the outstanding Series A shall have the right to participate in an amount equal to an aggregate of 30% of the Subsequent Financing on the same terms, conditions and price provided for in the Subsequent Financing.

Dividends. If the Corporation (as defined in the Certificate of Designation), at any time while any shares of Series A are outstanding, pays a dividend or distribution (other than one payable in shares of Common Stock or in Common Stock Equivalents) on shares of Common Stock, Holders as of the record date for such dividend or distribution on Common Stock shall be entitled to receive at the same time as such payment on Common Stock, and the Corporation shall pay, a dividend or distribution on each share of Series A equal to the per-share amount of the dividend or distribution on Common Stock multiplied by the number of shares of Common Stock into which such share of Series A was (on such record date) convertible (without regard to any limitations on conversion, including without limitation the Beneficial Ownership Limitation). Such dividend or distribution on Series A shall be paid in the same form as the dividend or distribution on Common Stock. The Series A shall not otherwise have any rights to dividends. The fair market value of any dividend or distribution to which a share of Series A has become entitled pursuant to the Certificate of Designation but which has not yet been paid shall, until such dividend or distribution has been paid on such share of Series A, be added to the Stated Value of such share of Series A.

Voting Rights. Notwithstanding anything in the Certificate of Designation to the contrary, , the Series A shall have no voting rights, except as required by applicable law or as expressly provided in the Certificate of Incorporation or this Certificate of Designation and shall not be entitled to any voting rights, other than any vote required by law or the Certificate of Incorporation.

Liquidation. In the event of a Liquidation Event, the Holders shall be entitled to receive in cash out of the assets of the Corporation, whether from capital or from earnings available for distribution to its stockholders (the “Liquidation Funds”), before any amount shall be paid to the holders of any of shares of Junior Stock, but pari passu with any Parity Stock then outstanding, an amount per share of Series A equal to the greater of (A) the Conversion Amount thereof on the date of such payment or (B) the amount per share such Holder would receive if such Holder converted such Series A into Common Stock immediately prior to the date of such payment, provided that if the Liquidation Funds are insufficient to pay the full amount due to the Holders and holders of shares of Parity Stock, then each Holder and each holder of Parity Stock shall receive a percentage of the Liquidation Funds equal to the full amount of Liquidation Funds payable to such Holder and such holder of Parity Stock as a liquidation preference, in accordance with their respective certificate of designation (or equivalent), as a percentage of the full amount of Liquidation Funds payable to all holders of Series A and all holders of shares of Parity Stock. To the extent necessary, the Corporation shall cause such actions to be taken by each of its Subsidiaries so as to enable, to the maximum extent permitted by law, the proceeds of a Liquidation Event to be distributed to the Holders in accordance with the Certificate of Designation. All the preferential amounts to be paid to the Holders pursuant to the Certificate of Designation shall be paid or set apart for payment before the payment or setting apart for payment of any amount for, or the distribution of any Liquidation Funds of the Corporation to the holders of shares of Junior Stock in connection with a Liquidation Event.

The foregoing summary of the terms of the Preferred Stock is qualified in its entirety by reference to the text of the Certificate of Designation, which is filed hereto as Exhibit 3.1 and is incorporated herein by reference.

Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including without limitation statements regarding the Company’s intended use of the net proceeds from the Offering, the filing and timing of a resale registration statement. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include: risks associated with market conditions; risks associated with the Company’s cash needs; and risks and uncertainties associated with the Company’s business and finances in general; and other risks and uncertainties set forth from time to time in the Company’s filings with the Commission. Any forward-looking statements contained in this Current Report on Form 8-K speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise.

Item 9.01 Financial Statements and Exhibits.

Exhibit Number		Description
3.1		Certificate of Designations of Preferences, Rights and Limitations of the Series A Convertible Non-Voting Preferred Stock
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ASPIRE BIOPHARMA HOLDINGS, INC.
	By:	/s/ Ernest Scheidemann
		Ernest Scheidemann
		Chief Financial Officer
Date: February 6, 2026

FAQ

What did Aspire Biopharma (ASBP) change with its Series A preferred stock?

Aspire Biopharma designated 25,000 shares of authorized preferred stock as Series A Convertible Non-Voting Preferred. These shares carry liquidation preference over common stock, can convert into common shares under defined pricing formulas, and include participation, dividend, and anti-dilution features described in the certificate of designation.

How is Aspire Biopharma’s Series A preferred stock converted into ASBP common shares?

Each Series A preferred share converts at the holder’s option into common stock at 80% of the lowest closing price over the five trading days before conversion. A floor price equal to 20% of Nasdaq’s “Minimum Price” applies, with additional adjustment mechanics outlined in the certificate of designation.

What ownership limits apply when Aspire Biopharma’s Series A preferred converts to common?

Conversions are subject to a beneficial ownership cap so a holder generally cannot exceed 4.99% of outstanding common shares. Investors may elect a higher limit up to 9.99% effective after 61 days, and overall conversions cannot exceed 19.99% of common shares without required shareholder approval under Nasdaq rules.

Where does Aspire Biopharma’s Series A preferred rank relative to ASBP common stock?

The Series A preferred ranks senior to common stock and any expressly junior securities for dividends and liquidation, pari passu with designated parity securities, and junior to any expressly senior securities. In a liquidation, holders are entitled to their stated value plus unpaid dividends before common stock receives any distribution.

Do Aspire Biopharma’s Series A preferred shares have voting rights?

The Series A preferred shares have no general voting rights. They may only vote where required by applicable law or as expressly provided in the company’s certificate of incorporation or the Series A certificate of designation, meaning common shareholders retain primary voting control in ordinary matters.

What dividend rights attach to Aspire Biopharma’s Series A preferred stock?

If common stock receives a cash or non-stock-equivalent dividend, each Series A preferred share receives an equivalent dividend on an as-converted basis. The amount equals the common dividend per share multiplied by the number of common shares into which that preferred share was then convertible on the record date.

What financing participation and price protection rights do ASBP Series A holders receive?

Until six months after issuance, Series A holders can participate for up to 30% of certain Subsequent Financings on the same terms. If new, non-exempt securities are issued below the then-current conversion price, the conversion price resets to the lower price, but not below the defined floor price level.